- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
From Polypharmacy to Personalized Care: Dr Nihar Desai Discusses Holistic Cardiovascular Care
In this episode of Managed Care Cast, Nihar Desai, MD, MPH, cardiologist and vice chief of Cardiology at the Yale School of Medicine, discusses therapies for cardiovascular conditions as they relate to patient adherence, polypharmacy, and health access.
Nihar R. Desai, MD, MPH, vice chief of cardiology at the Yale School of Medicine, joined The American Journal of Managed Care® to talk about critical topics in managing cardiovascular disease. He highlighted the importance of patient education, shared decision-making, and addressing cost and access barriers. Desai also explored multiple innovative strategies such as behavioral economics, personalized medicine, and digital tools to improve adherence.
He explained that a holistic approach to care is needed, particularly in addressing racial and ethnic disparities and integrating personalized medicine to achieve health equity. Additionally, he spoke on the promise of new therapies and the role of remote care in enhancing patient outcomes and quality of life.
Listen above or on one of these podcast services:
Inside the Center's MDD Value Model and Its Use of Dynamic Pricing
May 13th 2025Larragem Raines, MS, of the Center for Innovation & Value Research, discusses the organization's major depressive disorder (MDD) open-source value model, dynamic pricing, and the future role of artificial intelligence in care.
Listen
3 Maternal Risk Factors Linked to Elevated Offspring Blood Pressure
May 14th 2025Offspring born to mothers with prepregnancy obesity, gestational diabetes, or hypertensive disorders of pregnancy had higher systolic and diastolic blood pressure levels than those born to mothers without these risk factors.
Read More
Quantitative Magnetic Resonance Outcomes Suggest Gene Therapy Slows DMD Progression
May 14th 2025Delandistrogene moxeparvovec (Elevidys; Sarepta Therapeutics) appeared to protect muscle from progressive damage in patients with Duchenne muscular dystrophy (DMD) based on muscle quantitative magnetic resonance measures.
Read More
